Noninferior Immunogenicity and Consistent Safety of Respiratory Syncytial Virus Prefusion F Protein Vaccine in Adults 50–59 Years Compared to ≥60 Years of Age
Clinical Infectious Diseases · 05.08.2024
DOI: 10.1093/cid/ciae364 ↗Kurz gefasst
Randomisierte kontrollierte Studie in der Zeitschrift Clinical Infectious Diseases, online erschienen am 05.08.2024. Verfasst von Murdo Ferguson und 21 weiteren Autor:innen. Beteiligte Einrichtung: Colchester Research Group, Truro, Canada. Hauptthemen laut MEDLINE: Respiratory Syncytial Virus Vaccines, Respiratory Syncytial Virus Infections, Antibodies, Viral, Respiratory Syncytial Virus, Human. Die Arbeit wurde bisher 12-mal zitiert (Crossref) und nennt 30 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: GlaxoSmithKline Biologicals, BHP HRSA HHS, SA.
Abstract (Originalsprache)
Background
The adjuvanted respiratory syncytial virus (RSV) prefusion F protein–based vaccine (RSVPreF3 OA) is approved in adults aged ≥60 years. We evaluated RSVPreF3 OA immunogenicity and safety in adults aged 50–59 years without or with increased risk for RSV disease due to specific chronic medical conditions.
Methods
This observer-blind, phase 3, noninferiority trial included adults aged 50–59 years, stratified into 2 subcohorts: those with and those without predefined, stable, chronic medical conditions leading to an increased risk for RSV disease. Participants in both subcohorts were randomized 2:1 to receive RSVPreF3 OA or placebo. A control group of adults aged ≥60 years received RSVPreF3 OA. Primary outcomes were RSV-A and RSV-B neutralization titers (geometric mean titer ratios and sero-response rate differences) 1 month post-vaccination in 50–59-year-olds versus ≥60-year-olds. Cell-mediated immunity and safety were also assessed.
Results
The exposed population included 1152 participants aged 50–59 years and 381 participants aged ≥60 years. RSVPreF3 OA was immunologically noninferior in 50–59-year-olds versus ≥60-year-olds; noninferiority criteria were met for RSV-A and RSV-B neutralization titers in those with and those without increased risk for RSV disease. Frequencies of RSVPreF3-specific polyfunctional CD4+ T cells increased substantially from pre- to 1 month post-vaccination. Most solicited adverse events had mild-to-moderate intensity and were transient. Unsolicited and serious adverse event rates were similar in all groups.
Conclusions
RSVPreF3 OA was immunologically noninferior in 50–59-year-olds compared to ≥60-year-olds, in whom efficacy was previously demonstrated. The safety profile in 50–59-year-olds was consistent with that in ≥60-year-olds. Clinical Trial Registration ClinicalTrials.gov: NCT05590403.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Colchester Research Group, Truro, Canada.
- Institute of Laboratory Medicine and Vaccination Centre, Klinikum Würzburg Mitte, Campus Juliusspital, Würzburg Mitte, Würzburg, Germany.
- Infectología, Centro Medico Maffei, Buenos Aires, Argentina.
- Preventive Medicine Department, Immunocompromised Patient Immunization Unit, Son Espases University Hospital, Palma de Mallorca, Mallorca, Balearic Islands, Spain.
- Agnieszka Mital Centrum Badan Clinic, Elblag, Poland.
- Vacunar, Sede Las Cañitas, Buenos Aires, Argentina.
ORCID-Profile: Corinne Vandermeulen
Förderung
- GlaxoSmithKline Biologicals
- BHP HRSA HHS
- SA
Zitieren
APA
Ferguson, M., Schwarz, T. F., Núñez, S. A., Rodríguez-García, J., Mital, M., Zala, C., Schmitt, B., Toursarkissian, N., Mazarro, D. O., Großkopf, J., Voors-Pette, C., Mehta, H., Hailemariam, H. A., de Heusch, M., Salaun, B., Damaso, S., David, M. P., Descamps, D., Hill, J., …, & RSV OA=ADJ-018 Study Group (2024). Noninferior Immunogenicity and Consistent Safety of Respiratory Syncytial Virus Prefusion F Protein Vaccine in Adults 50–59 Years Compared to ≥60 Years of Age. Clinical Infectious Diseases. https://doi.org/10.1093/cid/ciae364
Vancouver
Ferguson M, Schwarz TF, Núñez SA, Rodríguez-García J, Mital M, Zala C, et al. Noninferior Immunogenicity and Consistent Safety of Respiratory Syncytial Virus Prefusion F Protein Vaccine in Adults 50–59 Years Compared to ≥60 Years of Age. Clinical Infectious Diseases. 2024. doi:10.1093/cid/ciae364
BibTeX
@article{Ferguson2024,
author = {Ferguson, Murdo and Schwarz, Tino F and Núñez, Sebastián A and Rodríguez-García, Juan and Mital, Marek and Zala, Carlos and Schmitt, Bernhard and Toursarkissian, Nicole and Mazarro, Dolores Ochoa and Großkopf, Josef and Voors-Pette, Christine and Mehta, Hemalini and Hailemariam, Hiwot Amare and de Heusch, Magali and Salaun, Bruno and Damaso, Silvia and David, Marie-Pierre and Descamps, Dominique and Hill, Judith and Vandermeulen, Corinne and Hulstrøm, Veronica and RSV OA=ADJ-018 Study Group, RSV OA=ADJ-018 Study Group},
title = {Noninferior Immunogenicity and Consistent Safety of Respiratory Syncytial Virus Prefusion F Protein Vaccine in Adults 50–59 Years Compared to ≥60 Years of Age},
journal = {Clinical Infectious Diseases},
year = {2024},
doi = {10.1093/cid/ciae364}
}
EUVIMED